A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is: Find out if patients receiving sorafenib will live longer. Find
out if sorafenib has any effect on patient reported outcomes. Find out if sorafenib prevents
the growth of or shrinks liver tumors and/or their metastases. Determine the pharmacokinetics
(PK) in patients with liver cancer.